Expert Review of Clinical Pharmacology · 2021 · 38 citations · 34 references
MedicinePharmacologyPsychiatryBehavioral HealthPsychopharmacologySubstance Use DisordersAnxiety AssessmentAnxiety Disorder PharmacotherapyAnxiety DisordersCannabinoid PharmacologyCannabis Use DisorderEndocannabinoid SystemGeneralized Anxiety Disorder AssessmentGeneralized Anxiety Disorder TreatmentPatient-reported Outcome MeasurementPatient-reported Outcome MonitoringSleep QualitySleep Quality AssessmentTreatment Of Anxiety Disorders
OBJECTIVES: Anxiety disorders are one of the most common reasons for seeking treatment with cannabis-based medicinal products (CBMPs). Current pharmacological treatments are variable in efficacy and the endocannabinoid system has been identified as a potential therapeutic target. This study aims to detail the changes in health-related quality-of-life (HRQoL) and clinical safety following CBMP therapy for generalized anxiety disorder. METHODS: A case series from the UK Medical Cannabis Registry was performed. Primary outcomes included changes from baseline in patient-reported outcome measures (the General Anxiety Disorder Scale (GAD-7), EQ-5D-5L (a measure of health-related quality of life), and Sleep Quality Scale (SQS)) at 1, 3 and 6 months. Statistical significance was defined as p<0.050. RESULTS: Sixty-seven patients were treated for generalized anxiety disorder. Statistically significant improvements were observed in GAD-7, EQ-5D-5L Index Value, EQ5D Visual Analog Scale, and SQS scores at 1, 3 and 6 months (p<0.050). Twenty-five (39.1%) patients reported adverse events during the follow-up period. CONCLUSION: Anxiety disorders are the most prevalent psychiatric illness type in the United Kingdom, with 8.2 million cases reported in 2010. Generalized anxiety disorder (GAD), the most common anxiety disorder, debilitates, and so reduces the quality of life of those who suffer from the condition.The efficacy of current treatments for GAD varies greatly from person-to-person. The endocannabinoid system in the human body is currently attracting a lot of attention in the scientific community as it can be targeted by chemicals in the cannabis plant to produce therapeutic effects in order to treat GAD. There is, however, a lack of studies investigating the effects of medicinal cannabis in GAD, and so this study aims to explore the drug's effect on quality of life in patients suffering from GAD.Sixty-seven patients who attended the Sapphire Clinics for medicinal cannabis treatment for GAD were included in the study. The results from this study highlight that medicinal cannabis may improve generalized anxiety disorder, general health-related quality of life, and sleep-specific outcomes at 1, 3, and 6 months after starting treatment. There was also a low number of severe, disabling, and life-threatening adverse events experienced by patients. Although this study explores the effects of medicinal cannabis in a real clinical setting, the results were not compared to other types of treatment. Future studies with a comparator are therefore needed before concluding the true effects of medicinal cannabis in patients with GAD.
34
Erik von Elm, Douglas G. Altman, Matthias Egger et al. · Journal of Clinical Epidemiology · 2008 · 16.4K citations · Full text
Public Health, Public Health Practice, Epidemiologic Methods +10
Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease
Valentina Cappello, Laura Marchetti, Paola Parlanti et al. · Scientific Reports · 2016 · 13.3K citations · Full text
Medicine, Neurobiology, Neuroscience +17
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Michael Herdman, Claire Gudex, Andrew Lloyd et al. · Quality of Life Research · 2011 · 10K citations · Full text
Hude Quan, Bing Li, Chantal Marie Couris et al. · American Journal of Epidemiology · 2011 · 5.9K citations · Full text
Health Professions, Health Services Administration, Clinical Classification Systems +16